CSL Ltd. recently announced that it now has exclusive rights to commercialize RAPIVAB, the influenza treatment that was created by BioCryst Pharmaceuticals Inc.
RAPIVAB, created during the collaboration between BioCryst and the U.S. government, is meant to be part of pandemic preparedness efforts. It is a single-dose intravenous treatment for patients with acute uncomplicated influenza.
In December 2014, experts approved the new treatment for use within the U.S. It has also received licensing for use in South Korea and Japan. As of today, estimates show that approximately 1 million people have received RAPIVAB for treatment.
BioCSL, a subsidiary of CSL Ltd. that has acquired the rights through CSL, will commercialize RAPIVAB. The subsidiary specializes in treatments to prevent influenza, including the use of pandemic and seasonal vaccines available on the global market.
“We are delighted to add RAPVIAB to our product portfolio,” John Anderson, general manager and senior vice president of bioCSL, said. “RAPIVAB is a specialty pharmaceutical that addresses an unmet medical need for the treatment of acute influenza in the hospital emergency room setting. It provides us with the opportunity to extend our influenza franchise to include both prevention and treatment options in seasonal and pandemic settings.”